5-(3-methylphenoxy)-2(1h)-pyrimidinone has been researched along with Alloxan Diabetes in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Handler, JA; Lipinski, CA; Ochman, AR; Reaume, AG; Saporito, MS | 1 |
1 other study(ies) available for 5-(3-methylphenoxy)-2(1h)-pyrimidinone and Alloxan Diabetes
| Article | Year |
|---|---|
The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Homeostasis; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred ICR; Pyrimidinones; Rats; Receptor, Insulin; src-Family Kinases | 2012 |